| 货号 | AF674 |
| 别名 | BP2; IBP2; IBP-2; IGF-binding protein 2; IGFBP-2; IGF-BP53; insulin-like growth factor binding protein 2 (36kD); insulin-like growth factor binding protein 2, 36kDa; insulin-like growth factor-binding protein 2 | 全称 | Insulin-like Growth Factor Binding Protein 2 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects human IGFBP-2 in direct ELISAs and Western blots. In direct ELISAs, approximately 5% cross-reactivity with recombinant mouse (rm) IGFBP-1 and rmIGFBP-2 and less than 1% cross-reactivity with recombinant human IGFBP-1, -3, -4, -5, -7 and rmIGFBP-3, -5, -6, and -7 is observed. |
| 使用方法 | Western Blot: 0.5 µg/mL Neutralization: Measured by its ability to neutralize IGFBP‑2 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. The Neutralization Dose (ND50) is typically 2.5-7.5 µg/mL in the presence of 0.2 µg/mL Recombinant Human IGFBP‑2 and 14 ng/mL Recombinant Human IGF‑II. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3485 (Human); 16008 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Insulin-like growth factor-binding protein 2 secreted by a tumorigenic cell line supports ex vivo expansion of mouse hematopoietic stem cells. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human IGFBP‑2 Glu40-Gln328 Accession # CAA34373 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBPs, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. Human IGFBP-2 cDNA encodes a 328 amino acid (aa) residue precursor protein with a putative 39 aa residue signal peptide that is processed to generate the 289 aa residue mature protein. IGFBP-2 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. During development, IGFBP-2 is expressed in a number of tissues. The highest expression level is found in the central nervous system. In adults, high expression levels are also detected in the central nervous system and in a number of reproductive tissues. IGFBP-2 binds preferentially to IGF-II, exhibiting a 2-10 fold higher affinity for IGF-II than for IGF-I. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
IGFBP‑2 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑2 Antibody. Recombinant Human IGFBP‑2 (Catalog # 674-B2) inhibits Recombinant Human IGF‑II (Catalog # 292-G2) induced proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF‑II (14 ng/mL) activity elicited by Recombinant Human IGFBP‑2 (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IGFBP‑2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF674). The ND50 is typically 2.5-7.5 µg/mL. |
